Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
News
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
MHRA authorises Bavarian Nordic’s chikungunya virus vaccine
HHS launches $500m universal vaccines initiative
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
Repare signs out-licensing deal with DCx Biotherapeutics
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
